Impetis Biosciences, a pharmaceutical research enterprise under the Tata group in Mumbai, India, has out-licensed two experimental drugs to Vyome Holdings, a company based in the United States. These drugs are designed to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, alopecia areata, and ulcerative colitis. Although the financial details of the transaction were not disclosed, sources indicate that milestone payments will be made to Impetis as the drugs progress through various research and commercialization stages. The drugs are classified as selective Janus kinase (JAK) inhibitors, which block specific enzymes associated with disease progression while addressing safety concerns linked to older, non-selective JAK inhibitors. Vyome stated that these in-licensed assets provide access to a global market estimated at $57 billion, reinforcing its strategy to source innovative treatments across the US-India corridor.